Safety Alerts & Recalls

What does this mean?

The new boxed warning emphasizes the importance of recognizing the rare but serious side effects of BOTULINUM TOXIN TYPE B (MYOBLOC), including unexpected loss of strength or muscle weakness, hoarseness or trouble talking (dysphonia), trouble saying words clearly (dysarthria), loss of bladder control, trouble breathing, trouble swallowing, double vision, blurred vision and drooping eyelids. These adverse events have been reported as early as several hours and as late as several weeks after treatment. If you are receiving treatment with BOTULINUM TOXIN TYPE B (MYOBLOC) please seek immediate medical attention if you develop any of these symptoms.

New Boxed Warning

In a follow up to the safety review conducted in early 2008, the FDA is requiring manufacturers to change the labeling for botulinum products, including BOTULINUM TOXIN TYPE B (MYOBLOC), to include a boxed warning about the risk of adverse events when the effects of the toxin spread beyond the injection site.

For more information, please visit: more information here

Source: FDA
Publication Date: 2009-05-01
Last Updated: 2009-12-05

Visit the medication page for the following drugs:

Share your story Share your story! Tell us how MediGuard has helped you or someone you love. Mobile graphic Download the MediGuard Mobile App to manage your prescription and over-the-counter medications, for free. Registration Info Taking multiple medications puts you at risk for possible drug-drug interactions Registration Info Monitor the medical treatment of you and your loved ones.